Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 07, 2023 3:12pm
143 Views
Post# 35773689

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSNO NO NO Canaduh.

Reread the new release "We believe that analysis of TIL clone expansion could become a helpful precision tool to provide an early indication of treatment response and serve as a potential guide to patient care with pelareorep. "

We "believe" is NOT proof. ONCY never states IS, for years all we have is "could", "might", "suggests"... stop the pumping hopium please..

IF ONCY had a confirmed biomarker, that had statistically demonstrated (to the acceptance of the FDA) a direct relationship to better outcomes, then ONCY would be talking accelerated approval.

And the reason the PanCan study was going to take several years, and why Matt stated that a Phase III in mBC would be a traditional Phase III, is ecactly beause they have not proven their biomarker translates into improved outcomes... for now that is only anecdotal.,,

Thsi was yet another nothing burger of a press release... Do bear in mind that you have been consistently wrong for the 3 years I've been reading your posts... always hopium... 

The market wants one thing... real, unassaisable data that shows Pela works, and a partner to get them across the line, because they absolutely cannot afford to run even 1 phase III alone... why does every trial partner fall shy of taking an equity stake..   answers ????

wishful pumping is wealth destroying for the unititiated...
<< Previous
Bullboard Posts
Next >>